NCT02075840 · OUTCOME

Time to Reach Cmax (Tmax) of Alectinib

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants · Source last updated 2026-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: hours
Interval / dispersion: Full Range
Time frame: Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)

Analysis population: The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.

Groups in this outcome

Alectinib

Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alectinib	144

Reported measurements

Baseline

Analysis denominator · Participants

Group	Source count
Alectinib	10

Values in hours · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Alectinib	6.03	Not reported	1.98	12.00	Not reported

Treatment - week 4

Analysis denominator · Participants

Group	Source count
Alectinib	9

Values in hours · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Alectinib	4.02	Not reported	2.00	8.00	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1.98
upper Limit
12.00
value
6.03
denoms
counts
group Id
OG000
value
10
units
Participants
title
Baseline
categories
measurements
group Id
OG000
lower Limit
2.00
upper Limit
8.00
value
4.02
denoms
counts
group Id
OG000
value
9
units
Participants
title
Treatment - week 4

denoms

counts
group Id
OG000
value
144
units
Participants

dispersion Type

Full Range

groups

description
Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG000
title
Alectinib

param Type

MEDIAN

population Description

The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.

reporting Status

POSTED

time Frame

Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)

title

Time to Reach Cmax (Tmax) of Alectinib

type

SECONDARY

unit Of Measure

hours

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice